
Antibodies anti-SARS-CoV2 time-course in patients and vaccinated subjects: an evaluation of the harmonization of two different methods

Ruggero Dittadi ^{1*}, Mara Seguso ¹, Isabella Bertoli ¹, Haleh Afshar ¹ and Paolo Carraro ^{1,*}

¹ Laboratory Medicine Unit, Ospedale dell'Angelo, ULSS3 Serenissima, Mestre, Italy; ruggero.dittadi@aulss3.veneto.it (R.D.); haleh.afshar@aulss3.veneto.it (H.A.); paolo.carraro@aulss3.veneto.it (P.C.)

* Correspondence: ruggero.dittadi@aulss3.veneto.it

Abstract: The time-course of antibodies anti SARS-CoV2 is not yet well elucidated, especially in people who underwent a vaccination campaign. In this study we measured antibodies anti-S1 and anti-RBD with two different methods both in patients and in vaccinated subjects.

108 specimens from 48 patients diagnosed as COVID-19 affected (time from the onset of symptoms from 3 to 368 days) and 60 specimens from 20 vaccinated subjects (collected after 14 days from the first dose, 14 days and 3 months after a second dose of Comirnaty) were evaluated.

We used an ELISA method that measure IgG against anti-Spike 1 and a chemiluminescence immunoassays that measure IgG anti-RBD.

In the patients, antibodies concentrations tend to decline after a few months with both methods, but persist relatively high up to nearly a year after symptoms.

In vaccinated subjects, antibodies were already detectable after the first dose, but after the booster they show a significant increase. However, the decrease is rapid, given that after 3 months after the second vaccination they are reduced to less than a quarter.

The conversion of the results into BAU units improves the relationship between the two methods. However, in vaccinated subjects there was no evidence of proportional error after the conversion, while in the patients the difference between the two methods remained significant.

Keywords: Immune response; SARS-CoV-2 antibodies response; Vaccination; method comparison; harmonization

1. Introduction

The determination of the antibodies against SARS-CoV-2 could be useful in epidemiological studies for estimating the spread of the infection and the lethality rate, in the serological diagnosis for individuals with mild or moderate symptoms and asymptomatic, in the first screening of

34 convalescent patients for plasma collection and in monitoring of the antibody response of
35 vaccinated subjects.

36 Long term time-course of antibodies response in Covid-19 disease is not yet fully determined.
37 Some studies show a significant decrease of antibodies concentrations within 3-4 months from the
38 onset of symptoms [1-4]. Others reports find constant or only slightly decreased levels starting
39 from 4 months and up to 10 months from the symptoms' onset [5-8], even when specific
40 neutralizing antibodies [9] were measured. In particular, the time-course of the antibody response
41 seems variable also according to the method used [8,10]. On the other hand, antibodies seem to
42 persist through 4-6 months in vaccinated subjects [11,12].

43 The aim of this work is to evaluate the performance of 2 methods for the determination of
44 antibodies to SARS-CoV-2 in patients with a long-term time-course. We also evaluated the
45 presence of antibodies in a little cohort of subjects vaccinated with Comirnaty vaccine.

46 **2. Materials and Methods**

47 We recruited symptomatic subjects who presented at the dell'Angelo Hospital (Mestre, Italy) in
48 March 2020, resulted affected by COVID-19 according to both clinical and laboratory criteria.
49 Forty-eight patients with known date of symptoms' onset were included in the study (41 males, 7
50 females, median age 62.3 years, minimum 28, maximum 87). The median time from the onset of
51 symptoms was 26 days (minimum 3, maximum 368). A total of 108 withdrawals were collected.
52 Number of withdrawals per patient and other patients' characteristics were reported in table 1.

53 Moreover, serum samples were collected from 20 healthcare workers after 14 days from the first
54 dose, 14 days and 3 months after a second dose of Comirnaty vaccine (BNT162b2, BioNTech/Pfizer,
55 Mainz, Germany/New York, United States). All subjects underwent periodical nasopharyngeal
56 swab testing (every 2 or 3 weeks) and resulted negative to the antibodies determination prior to
57 vaccine administration.

58 The specimens were stored at -80°C until the assay.

59 IgG were measured with an ELISA method, the anti-SARS-CoV-2 QuantiVac ELISA IgG
60 (Euroimmun, Lubeck, Germany) and a two-step chemiluminescence microparticle immunoassays
61 SARS-CoV-2 IgG anti-RBD (SNIBE, Shenzhen, China).

62 Both the assays were performed according to the manufacturer's instructions.

63 The good analytical characteristics of the two methods and the satisfactory correlation with the
64 neutralization tests were previously evaluated and confirmed [13-15]. The concentrations were
65 measured taking into consideration the previously determined linearity of the respective methods
66 [16].

67

68 **Table 1** - Characteristics of the studied patients.

69 *The disease severity was classified according the WHO guidance "Laboratory testing for coronavirus disease (COVID-19) in*
70 *suspected human cases")*

71

Symptoms at the onset of disease	Frequency (%)
Fever	75.0
Cough	60.4
Dyspnoea	29.2
Nausea	8.3
Asthenia	6.3
Others	10.5
Disease severity	n of patients
Mild	9
Moderate	16
Severe	11
Critical	12
n of withdrawals	n patients
1	19
2	12
3	7
4	7
5	2
6	1

72

73

74 In the ELISA Euroimmun method, the concentrations of the antibodies against the S1 protein were
75 determined through the interpolation with a six-point calibration curve (from 1 to 120 Relative
76 Units/mL). Results <8 RU/mL were considered as negative, results >8 RU/mL and ≤11 RU/mL were
77 considered as indeterminate and >11 RU/mL as positive.

78 The IgG anti-RBD method measure antibodies against receptor binding domain of the S1 protein,
 79 were carried out on the analyser Maglumi 800 (SNIBE, Shenzhen, China), and use a nine-point
 80 master curve (from 1 to 100 Arbitrary Units/mL) periodically adjusted by a 2-point calibration.
 81 Results ≥ 1 AU/mL were considered as positive.

82 The statistical analyses were performed with MedCalc © Software, Version 7.4.2.0 (MedCalc
 83 Software, Mariakerke, Belgium).

84

85 3. Results

86 The overall concordance rate between methods was 89.8% (kappa statistics, 0.54; 95% CI, 0.30–0.78).

87 The results of patients' specimens were subdivided into 7 groups, for which the qualitative
 88 performance was evaluated (Table 2).

89

90 **Table 2** - Sensitivity and antibodies levels of ELISA and Maglumi methods in the different patient's specimens subdivided in
 91 time frames according to the day from the onset of symptoms

92 Asterisks represent the classes of cases significantly different from that with higher concentrations.

93

		Positivity rate		ELISA levels (RU/mL)			Maglumi levels (AU/mL)		
Days from symptoms' onset	n of specimens	ELISA	Maglumi	25 perc	Median	75 perc	25 perc	Median	75 perc
≤ 11 *	17	41.2%	76.5%	2,4	10,3	37,1	1,0	3,1	14,1
12-16 *	15	73.3%	80.0%	6,7	68,1	404,0	2,3	24,9	50,6
17-22	14	100.0%	100.0%	76,80	191,5	438,0	25,6	48,8	58,1
23-43	16	100.0%	100.0%	137,5	250,5	448,5	43,2	50,5	61,5
46-72	15	100.0%	100.0%	183,2	259,2	330,2	49,8	82,7	126,0
81-162 *	16	93.7%	100.0%	57,8	102,6	149,0	23,1	34,6	53,1
168-371 *	15	86.7%	100.0%	29,4	39,6	110,3	13,9	22,2	48,1

94

95 The quantitative relationship showed a satisfactory correlation, although with relative disperse
 96 distribution of cases. Passing-Bablock regression resulted "*Maglumi*= 0.284 (0.24/0.33) +0.581
 97 (-0.21/2.64) *ELISA*" (Fig. 1 A).

98 The differences in concentration between age groups were statistically significant for both methods
99 (Kruskall-Wallis test $p=0.00002$ for both Maglumi and ELISA).

100 The antibodies' levels showed a similar time-course with the two methods. After a rapid increase, the
101 concentrations begin to decrease slightly after about 80-100 days (figure 2 and 3).

102 The ELISA method showed a sensitivity of about 87% after 180 days, while the sensitivity of Maglumi
103 remains 100%.

104 The results of the determination with the two methods in the 13 patients with more than one blood
105 collection at least up to 180 days after the onset of symptoms were shown in figure 4.

106

107



108 **Figure 1.** Correlations between ELISA and Maglumi SARS-CoV-2 IgG levels in patients' specimens. The trend lines
109 represent the Passing-Bablock correlation

110 **A** Concentrations expressed in Arbitrary Units [$Maglumi = 0.581 (-0.21/2.64) ELISA + 0.284 (0.24/0.33)$]

111 **B** Concentrations expressed as BAU [$Maglumi = 2.45 (-1.6 / + 10.6) + 0.39 (0.33 / 0.46) ELISA$]

116 **A**

112 **B**



117

13

118

114

119

115

120

121

122

123

124


125

126

127 **Figure 2.** Distribution of IgG levels of the single specimens measured by ELISA in relation to the days since the
128 onset of symptoms.

129 *In abscissa are reported the days from the onset of symptoms, in ordinate the concentrations of IgG. The solid line connects*
130 *the median concentrations of IgG for each class of cases, the dotted line connects the respective 25°-75° percentile.*

131



132

133

134

135

136

137

138


139

140

141 **Figure 3.** Distribution of IgG levels of the single specimens measured by Maglumi in relation to the days since
142 the onset of symptoms.

143 *In abscissa are reported the days from the onset of symptoms, in ordinate the concentrations of IgG. The solid line connects*
144 *the median concentrations of IgG for each class of cases, the dotted line connects the respective 25°-75° percentile.*

145



146

147

148

149

150

151

152



153

154 **Figure 4.** Spaghetti plot of the 13 patients with more than one withdrawal in more than 180 days from the onset
155 of symptoms, measured by Maglumi (A) and ELISA (B).

156

160 A

157 B



161 .58

162 159

163 All the vaccinated subjects were positive 15 days after the first inoculum with Maglumi method,
164 while with the ELISA method 4/22 cases resulted negative.

165 Fifteen days after the booster all the samples were positive with both methods, and the concentrations
166 resulted more than 20 times the first withdrawal (table 3).

167 The correlations between the two methods resulted satisfactory, especially after the second dose (figure 5
168 and 6). The Passing-Bablock regression were: $Maglumi = -0.89(-6.1/+1.2) + 0.59 (0.47/0.78) ELISA$ for the
169 specimens after the first dose and $Maglumi = -52.4(-107/+19.2) + 0.85 (0.74/0.92) ELISA$ for the specimens
170 after the second administration.

171 Three months after the second dose the levels of antibodies drastically decrease (table 3). The median of
172 the percentage of the concentrations compared to those found 15 days after the second dose was 21%
173 (10°-90° perc 11-33%) with Maglumi and 24.4% (10°-90° perc 13-33%) with ELISA.

174

175

176

177

178

179 **Tab. 3** – Concentrations of antibodies anti SARS-CoV2 in the vaccinated subjects, expressed both in Arbitrary Units and in
 180 BAU

181

		ELISA levels		Maglumi levels	
		Median	Interquartile range	Median	75 perc
Arbitrary Units/mL	15 days after the first dose	27.2	16.4 – 42	18.1	6.6 - 27.7
	15 days after the second dose	704.5	388.5 – 940	499	335.9 – 756.8
	3 months after the second dose	129.6	95.2 – 244	84.6	47.7 – 195
Binding Antibody Units/mL (WHO)	15 days after the first dose	87	58.1 – 113.8	78.4	30.8 – 113
	15 days after the second dose	2254	1243 – 3008	2160	1454 – 3277
	3 months after the second dose	366.1	206.7 - 844	414.7	305 - 781

182

183 The Passing-Bablok regression between the two methods was: $Maglumi = -16.2(-37.5/+5.7) + 0.78$
 184 $(0.65/0.98)$ ELISA (Fig. 7).

185 Correction factors versus the international standard WHO 20/136 were determined for both assays
 186 (4.33 for Maglumi and 3.2 for ELISA). The correlations between the two methods after transformation
 187 into Binding Arbitrary Units (BAU) resulted in $Maglumi = 2.45 (-1.6 / + 10.6) + 0.39 (0.33 / 0.46)$ ELISA in
 188 patients, $Maglumi = -5.1 (-26.8 / + 5.0) + 0.82 (0.64 / 1.07)$ ELISA in subjects vaccinated after the first dose
 189 and $Maglumi = -227.9 (-464 / + 69.9) + 1.14 (0.99 / 1.25)$ ELISA in subjects vaccinated after the second
 190 dose. Three months after the second dose the correlation is $Maglumi = -72.8 (-166.8 / + 24) + 1.07 (0.88 /$
 191 $1.35)$ ELISA.

192

193

194

195


196
197
198
199
200
201
202
203
204
205
206
207

Figure 5. Correlation between ELISA and Maglumi methods in vaccinated subjects after the first dose. The trend lines represent the Passing-Bablok correlation


A Concentrations expressed in Arbitrary Units [$Maglumi = -0.89(-6.1/1.2) + 0.59 (0.47/0.78) ELISA$]

B Concentrations expressed as BAU [$Maglumi = -5.1 (-26.8 / + 5.0) + 0.82 (0.64 / 1.07) ELISA$]

A



B



208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223


224 **Figure 6.** Correlation between ELISA and Maglumi methods in vaccinated subjects 15 days after the second dose. The
225 trend lines represent the Passing-Bablock correlation

226 **A** Concentrations expressed in Arbitrary Units [$Maglumi = -52.4(-107/+19.2) + 0.85 (0.74/0.92)$]


227 **B** Concentrations expressed as BAU [$Maglumi = -227.9 (-464 / + 69.9) + 1.14 (0.99 / 1.25) ELISA$]

228

229 **A**



B



230

231

232


233 **Figure 7.** Correlation between ELISA and Maglumi methods in vaccinated subjects 3 months after the second dose.
234 The trend lines represent the Passing-Bablock correlation

235 **A** Concentrations expressed in Arbitrary Units [$Maglumi = -16.2(-37.5/+5.7) + 0.78 (0.65/0.98) ELISA$]


236 **B** Concentrations expressed as BAU [$Maglumi = -72.8 (-166.8 / + 24) + 1.07 (0.88 / 1.35) ELISA$]

237

238 **A**



B



239

240 4. Discussion

241 In this study, the performance of two assays for the determination of antibodies anti SARS-CoV2 in
242 patients with samples up to 10-12 months from the onset of symptoms were compared. With both
243 methods, antibodies concentrations tend to decline after a few months, but the levels persist relatively
244 high up to nearly a year after symptoms (Tab.2). Our data, especially those obtained with Maglumi,
245 were approximately in accord with a model of the IgG anti-S decay in patients, that established a
246 half-life of 229 days [17]. Positivity rates remains 100% with the Maglumi method, while they drop to
247 87% with the ELISA method.

248 In vaccinated subjects, the presence of high concentrations of antibodies is already detectable after the
249 first dose, but after the booster they show a significant increase, about 20 times compared to the first
250 administration and on average 3 times the maximum concentrations reached by the patients after
251 about two months from the onset of symptoms. This result is in agreement with previous findings for
252 the method used [13,18,19]. However, in vaccinated subjects the decrease in antibody concentrations
253 is more rapid, given that after 3 months after the second vaccination they are reduced to less than a
254 quarter. The correlations between the two methods are always acceptable, but while in the patients
255 the results are scattered and the ELISA method has 3-4 times higher levels of Maglumi, in vaccinated
256 subjects the concentrations between the two methods are closer and much better correlated. Moreover,
257 the conversion of the results into BAU units improves the relationship between the two methods.
258 However, only in vaccinated subjects there was no evidence of proportional error after the conversion,
259 while in the patients the difference between the two methods remained significant. The methods
260 measure antibodies directed against the Spike 1 protein, but Maglumi more specifically determines
261 antibodies against the receptor domain. This difference may partly justify the results in the patients.
262 Considering that only Ab anti Spike should be expressed in vaccinated patients, it could be
263 speculated that the greater heterogeneity of antibodies pattern in patients could cause the less close
264 correlation between the two methods found in these subjects. However, the decrease in
265 concentrations a few months after vaccination does not necessarily mean a reduction in protection. It
266 is in fact possible that the protection is not directly proportional to the mere presence of antibodies,
267 given the persistence of T-cell memory after infection [6]. In conclusion, both methods have

268 comparable behaviors, both in patients and in vaccinated subjects. In both cases the antibody
269 concentrations peaked and then decrease. However, in vaccinated subjects the peak reached a much
270 higher levels than in the patients, and the decrease was more rapid. Three months after the second
271 injection they showed concentrations comparable to those of patients after more than 6 months from
272 the onset of the disease. A peculiar finding of the study was the failure of the BAU conversion in the
273 harmonization of different methods only in patients' specimens. Further studies will be required to
274 clarify the different behavior between patients and vaccinated subjects.

275

276 **Author Contributions:** Conceptualization, R.D. and P.C.; sample collection, R.D., I.B. and H.A.; methodology, M.S. I.B. and H.A.; formal
277 analysis, R.D.; writing—original draft preparation, R.D.; writing—review and editing, R.D., M.S., H.A. and P.C.; supervision, P.C. All authors
278 have read and agreed to the published version of the manuscript.

279 **Funding:** This research received no external funding.

280 **Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki.

281 The Ethical committee for clinical trials, ULSS3 Serenissima, Venice, approved the study (Approval n.149/A CESC).

282 **Acknowledgments:** We acknowledge Medical Systems and Euroimmun for kindly supplying reagents without any influence in
283 study design and data analysis.

284 **Conflicts of Interest:** The authors declare no conflict of interest.

285 References

- 286 1. Ibarrondo, F.J.; Fulcher, J.A.; Goodman-Meza, D.; Elliott, J.; Hofmann, C.; Hausner, M.A. Ferbas, K.G.; Tobin,
287 N.H.; Aldrovandi, G.M.; Yang, O.O. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild
288 Covid-19. *N Engl J Med* 2020, 383, 1085-1087. doi: 10.1056/NEJMc2025179.
- 289 2. Terpos, E.; Mentis, A.; Dimopoulos, M.A. Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19. *N Engl J*
290 *Med* 2020, 383, 1695. doi: 10.1056/NEJMc2027051.
- 291 3. Kutsuna, S.; Asai, Y.; Matsunaga, A. Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19. *N Engl J Med*
292 2020, 383, 1695-1696. doi:10.1056/NEJMc2027051.
- 293 4. Long, Q.; Tang, X.; Shi, Q.; Li, Q.; Deng, H.; Yuan, J. et al. Clinical and immunological assessment of
294 asymptomatic SARS-CoV-2 infections. *Nat Med* 2020, 26, 1200-1204. doi: 10.1038/s41591-020-0965-6.
- 295 5. Gudbjartsson, D.F.; Norddahl, G.L.; Melsted, P.; Gunnarsdottir, K.; Holm, H.; Eythorsson, E.; Arnthorsson,
296 A.O.; Helgason, D.; Bjarnadottir, K.; Ingvarsson, R.F. et al. Humoral Immune Response to SARS-CoV-2 in
297 Iceland. *N Engl J Med* 2020; 383:1724-1734. doi: 10.1056/NEJMoa2026116G
- 298 6. Dan, J.M.; Mateus, J.; Kato, Y.; Hastie, K.M.; Yu, E.D.; Faliti, C.E.; Grifoni, A.; Ramirez, S.I.; Haupt, S.; Frazier,
299 A. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science*.
300 2021;371(6529): eabf4063. doi: 10.1126/science.abf4063. Epub 2021 Jan 6.
- 301 7. Dispinseri, S.; Secchi, M.; Pirillo, M.F.; Tolazzi, M.; Borghi, M.; Brigatti, C.; De Angelis, M.L.; Baratella, M.;
302 Bazzigaluppi, E.; Venturi, G. et al. Neutralizing antibody responses to SARS-CoV-2 in symptomatic

- 303 COVID-19 is persistent and critical for survival. *Nat Commun.* 2021;12(1):2670. doi:
304 10.1038/s41467-021-22958-8
- 305 8. Favresse, J.; Eucher, C.; Elsen, M.; Gillot, C.; Van Eeckhoudt, S.; Dogné, J.M.; Douxfils, J. Persistence of An-
306 ti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection. *Microorganisms.* 2021;9(3):556. doi:10.3390/microorganisms9030556. PMID: 33800489
- 307
- 308 9. Lau, E.H.Y.; Tsang, O.T.Y.; Hui, D.S.C.; Kwan, M.Y.W.; Chan, W.H.; Chiu, S.S.; Ko, R.L.W.; Chan, K.H.;
309 Cheng, S.M.S.; Perera, R.A.P.M. et al. Neutralizing antibody titres in SARS-CoV-2 infections. *Nat Commun.*
310 2021;12(1):63. doi: 10.1038/s41467-020-20247-4. PMID: 33397909
- 311 10. Dittadi, R.; Afshar, H.; Carraro, P. Two SARS-CoV-2 IgG immunoassays comparison and time-course profile
312 of antibodies response. *Diagn Microbiol Infect Dis.* 2021;99(4):115297. doi:
313 10.1016/j.diagmicrobio.2020.115297. Epub 2020 Dec 24.
- 314 11. Doria-Rose, N.; Suthar, M.S.; Makowski, M.; O'Connell, S.; McDermott, A.B.; Flach, B.; Ledgerwood, J.E.;
315 Mascola, J.R.; Graham, B.S.; Lin, B.C.; et al. mRNA-1273 Study Group. Antibody Persistence through 6
316 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.
317 *N Engl J Med.* 2021 Jun 10;384(23):2259-2261. doi: 10.1056/NEJMc2103916. Epub 2021 Apr 6
- 318 12. Widge, A.T.; Roupshael, N.G.; Jackson, L.A.; Anderson, E.J.; Roberts, P.C.; Makhene, M.; Chappell, J.D.; Den-
319 ington, M.R.; Stevens, L.J.; Pruijssers, A.J. et al. mRNA-1273 Study Group. Durability of Responses after
320 SARS-CoV-2 mRNA-1273 Vaccination *N Engl J Med.* 2021 Jan 7;384(1):80-82. doi: 10.1056/NEJMc2032195.
321 Epub 2020 Dec 3
- 322 13. Müller, L.; Andrée, M.; Moskorz, W. Age-dependent immune response to the BioNtech/Pfizer BNT162b2
323 COVID-19 vaccination. *Clin Infect Dis.* 2021 doi: 10.1093/cid/ciab381. published online April 27
- 324 14. Rubio-Acero, R.; Castelletti, N.; Fingerle, V.; Olbrich, L.; Bakuli, A.; Wölfel, R.; Giral, P.; Müller, K.; Jochum, S.;
325 Strobl, M. et al. KoCo19 study team. In Search of the SARS-CoV-2 Protection Correlate: Head-to-Head
326 Comparison of Two Quantitative S1 Assays in Pre-characterized Oligo-/Asymptomatic Patients. *Infect Dis*
327 *Ther.* 2021 Jun 16:1-14. doi: 10.1007/s40121-021-00475-x. Online ahead of print
- 328 15. Padoan, A.; Bonfante, F.; Cosma, C.; Di Chiara, C.; Sciacovelli, L.; Pagliari, M.; Bortolami, A.; Costenaro, P.;
329 Musso, G.; Basso, D. et al. Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: compar-
330 ison with neutralization titers. *Clin Chem Lab Med.* 2021 Apr 14;59(8):1444-1452. doi: 10.1515/cclm-2021-0313.
331 Print 2021 Jul 27.
- 332 16. Dittadi, R.; Bertoli, I.; Carraro, P. Reportable range of quantitative assays for SARS-CoV-2 antibodies deter-
333 mination: An overlooked issue? *Ann Clin Biochem.* 2021 May 29:45632211020047. doi:
334 10.1177/00045632211020047. Online ahead of print.
- 335 17. Wheatley, A.K.; Juno, J.A.; Wang, J.J.; Selva, K.J.; Reynaldi, A.; Tan, H.X.; Lee, W.S.; Wragg, K.M.; Kelly, H.G.;
336 Esterbauer, R. et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. *Nat*
337 *Commun.* 2021 Feb 19;12(1):1162. doi: 10.1038/s41467-021-21444-5.
- 338 18. Padoan, A.; Dall'Olmo, L.; Rocca, F.D.; Barbaro, F.; Cosma, C.; Basso, D.; Cattelan, A.; Cianci, V.; Plebani, M.
339 Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers. *Clin*
340 *Chim Acta.* 2021; 519:60-63. doi: 10.1016/j.cca.2021.04.006. Epub 2021 Apr 20
- 341 19. Lo Sasso, B.; Giglio, R.V.; Vidali, M.; Scazzone, C.; Bivona, G.; Gambino, C.M.; Ciaccio, A.M. Agnello, L.;
342 Ciaccio, M. Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vac-
343 cine. *Diagnostics (Basel).* 2021;11(7):1135. doi: 10.3390/diagnostics11071135
- 344